BPC-157 and TB-500: a complete guide to evidence and safety

What BPC-157 and TB-500 are (and why they come up together)

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419³⁴. It is a partial sequence of a protein described in human gastric juice², and the group that first described it, at the University of Zagreb, reports that it is stable in human gastric juice¹. That stability is one reason it has been studied by mouth as well as by parenteral and topical routes¹³.

TB-500 is a different molecule with no chemical relationship to BPC-157. It is the N-acetylated fragment of residues 17 to 23 of thymosin β4 (Ac-LKKTETQ), identified by an anti-doping laboratory inside a product sold under that name¹⁶ and described as a synthetic version of an active region of the protein³⁴. Full-length thymosin β4 is a natural 43-amino-acid protein whose sequence was published in 1981 from calf thymus¹⁴, and it is the main actin-sequestering peptide in mammalian tissue¹⁵.

They come up together because they share the same story, soft-tissue repair, and because they are often sold together, alone or in blends. For a plain-language introduction, see BPC-157 and TB-500: what the lab studies in repair; the logic of combinations is in GLOW, KLOW and Wolverine: the logic of regenerative blends. This guide brings together what a physician needs and links to our deeper analyses.

BPC-157 mechanism of action: vessels, fibroblasts and nitric oxide

BPC-157's mechanism has been described almost entirely in cell cultures and rats. The best-documented pieces are three:

• Angiogenesis. In the chick chorioallantoic membrane and in endothelial tube-formation assays, BPC-157 increased vessel density; in rats with hind-limb ischemia it sped up the recovery of blood flow. In human endothelial cells it increased the expression and internalization of the VEGFR2 receptor (not VEGF-A) and activated the VEGFR2-Akt-eNOS pathway⁵. A University of Utah review adds ERK1/2 signaling and nitric oxide synthesis as axes of the effect¹².
• Tendon fibroblasts. BPC-157 did not directly increase tendon fibroblast proliferation, but it did increase their survival under oxidative stress, their migration and their spreading, with dose-dependent activation of the FAK-paxillin pathway².
• Repair mediators. A 2025 systematic review summarizes that BPC-157 increases expression of the growth hormone receptor and of several cell-growth and angiogenesis pathways, and lowers inflammatory cytokines¹¹.

The animal results rest on that base. In rats with a transected Achilles tendon, BPC-157 improved load to failure, modulus of elasticity and the functional index, and reduced the tendon defect⁴. The Zagreb group has also published healing of anastomoses, fistulas and gastrointestinal lesions in rats¹. The 2025 systematic review found functional, structural and biomechanical improvements in muscle, tendon, ligament and bone models¹¹. The study-by-study walk-through is in BPC-157 in the laboratory: tendon, gut and blood vessels.

One caveat: much of this animal literature comes from the same group that described the peptide¹⁴, and independent replication is scarce. We put numbers on it in BPC-157: from Rogan's podcast to an FDA vote.

TB-500 and thymosin β4: fragment vs protein

Almost everything attributed to TB-500 comes from studies of full-length thymosin β4. In rats with full-thickness wounds, the protein applied topically or intraperitoneally increased re-epithelialization by 42% at 4 days and by up to 61% at 7 days, with more collagen and more vessels¹⁸. In mice with coronary ligation it formed a complex with PINCH and integrin-linked kinase (ILK), activated Akt and improved cardiac function¹⁹. In rats and mice it also accelerated hair growth by promoting the migration of follicle stem cells³³; we review that in Peptides and hair loss: copper, thymosin β4 and biomimetics against the evidence.

The link to TB-500 is a 2003 experiment: a seven-amino-acid actin-binding motif proved essential for the angiogenic activity, and in endothelial migration and vessel-sprouting assays the full protein and that motif had near-identical activity at about 50 nM¹⁵. But the acetylated fragment sold as TB-500 has barely been studied on its own. An anti-doping laboratory found in rats that it is broken down mainly to Ac-LK, that the metabolite Ac-LKK is detectable for up to 72 hours, and that in fibroblasts only the metabolite Ac-LKKTE showed significant wound-healing activity versus control; the authors suggest the activity attributed to TB-500 may come from that metabolite rather than the parent molecule¹⁷.

A naming problem complicates any reading: on the market, "TB-500" is also used for full-length thymosin β4. In a 2026 study of rats with a repaired Achilles tendon, the authors describe the TB-500 they used as "synthetic thymosin β4"; in that model TB-500 significantly improved load to failure, BPC-157 improved histological scores without significance on the totals, and the combination added no further benefit²⁴. We expand on this in TB-500 is not thymosin beta-4: fragment vs protein.

What the human evidence shows

This is where the gap between these peptides' reputation and the data is widest. For BPC-157, everything published in humans is three pilot studies by the same lead author, at a private clinic, with no control group:

• Knee pain (2021). A retrospective chart review with a phone survey of 16 patients after an intra-articular injection (4 of them with BPC-157 plus thymosin β4): 14 of 16 reported relief. No validated function or quality-of-life scales were used⁸.
• Interstitial cystitis (2024). 12 women who had not responded to pentosan polysulfate, treated in a single cystoscopic procedure; 10 of 12 reported complete resolution of symptoms and no adverse events were reported⁹.
• Intravenous safety (2025). 2 participants who had already received BPC-157 before; two infusions on consecutive days, with no measurable effects on cardiac, liver, kidney or thyroid markers or on glucose¹⁰.

Independent reviews agree. The 2025 systematic review included 36 studies, 35 preclinical and 1 clinical, and wrote: "No clinical safety data were found"¹¹. The Utah review called the human data "extremely limited" and concluded that BPC-157 "should be considered investigational"¹². A 2026 pharmaceutical review counts fewer than 30 subjects across the three pilots, none using a standardized pharmaceutical preparation, and no completed phase 2 trial¹³.

Papers from the Zagreb group mention trials in inflammatory bowel disease under the code PL 14736 in which the peptide was reportedly safe¹⁴, but we found no published results. The international registry ClinicalTrials.gov lists a phase 1 trial in healthy volunteers that started in 2015, with 42 planned participants, whose status is "unknown" and which has no posted results³⁰. The first randomized, double-blind, placebo-controlled trial we found is a phase 2 in acute MRI-confirmed grade II hamstring strains, with 120 planned participants, recruiting since February 2026 and with an estimated primary completion in February 2027²⁹.

For full-length thymosin β4 there are controlled trials, though small. In a phase 3 in neurotrophic keratopathy with 18 patients, complete healing at 4 weeks was 6 of 10 versus 1 of 8 with placebo (P = 0.0656), missing the primary endpoint; two weeks after treatment ended, the difference was significant (P = 0.0359). Three authors were employees of the company developing the product or of its parent company²¹. In a phase 2 in severe dry eye with 9 patients, the drops were associated with 35.1% less discomfort and 59.1% less corneal staining than vehicle²². In stasis and pressure ulcers, a review by its investigators summarizes two phase 2 trials in which the protein sped up healing by almost a month in the patients who did heal²⁰. And a phase 1 of the intravenous recombinant protein in 84 healthy volunteers showed no dose-limiting toxicities or serious adverse events²³.

For TB-500, the fragment, there is nothing: the FDA wrote that it "has not identified any human exposure data" for products containing the thymosin β4 fragment²⁷.

BPC-157 vs TB-500: how they compare

Much of the confusion comes from crediting one molecule with another's data. This comparison sums up what is known about each:

• Origin. BPC-157: a synthetic fragment of a gastric juice protein². TB-500: an acetylated synthetic fragment of an intracellular protein, thymosin β4¹⁶³⁴.
• Proposed mechanism. BPC-157: VEGFR2-Akt-eNOS, nitric oxide and fibroblast migration via FAK-paxillin²⁵. TB-500: thymosin β4's actin-binding motif, angiogenic in culture¹⁵; its own activity may depend on a metabolite¹⁷.
• Animal data. BPC-157: broad and consistent, concentrated in one group¹⁴¹¹. TB-500: scarce for the fragment; broad for the full protein¹⁷¹⁸¹⁹.
• Human data. BPC-157: three uncontrolled pilots, fewer than 30 people¹³. TB-500: none²⁷. Full-length thymosin β4: phase 1 to 3 trials, small and with mixed results²¹²²²³.
• Pharmacokinetics. BPC-157: half-life under 30 minutes in rats and dogs⁶. TB-500: metabolites detectable in rat urine for up to 72 hours¹⁷.
• Sport. BPC-157: World Anti-Doping Agency list, section S0. TB-500: section S2.3, together with thymosin β4 and its derivatives²⁸.

The only study that compared them head to head, in rats, found no extra benefit from combining them²⁴. No combination has been studied in humans.

Safety and adverse effects: what is known and what isn't

The safety problem with these peptides is not a proven harm signal but the lack of data to rule one out. In animals, the most complete toxicology program for BPC-157 (mice, rats, rabbits and dogs) showed no genetic or embryo-fetal toxicity, local irritation was mild, and in dogs there was a drop in creatinine at the highest dose that reversed within 2 weeks⁷. In humans, the pilots reported no adverse events, but with 12 and 2 participants they cannot detect uncommon effects⁹¹⁰.

The FDA sums up its concerns this way: compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration," may have complexities with peptide-related impurities, and the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans." For the thymosin β4 fragment it adds a risk of immunogenicity "due to the potential for aggregation" and impurities²⁷.

The most frequent question is cancer. BPC-157 stimulates the VEGFR2 receptor and vessel formation⁵, and β-thymosins, including thymosin β4, are involved not only in normal cell migration but also in tumor metastasis²⁵. A 2026 review of unregulated peptides lists pathological angiogenesis and carcinogenesis among their potential risks, alongside product contamination, impurities and inaccurate dosing²⁶. No human data confirm or rule out that concern: it is a theoretical risk derived from the mechanism, and it cannot be measured without trials with long follow-up.

The 2025 systematic review adds another source of risk, unrelated to the molecule itself: adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety¹¹. That part depends on product quality, which we cover next.

Quality, pharmacokinetics and stability

The only formal pharmacokinetic study of BPC-157, in rats and beagle dogs, found an elimination half-life under 30 minutes, linear kinetics, and intramuscular bioavailability of 14–19% in rats and 45–51% in dogs; the peptide is quickly broken down into small fragments and amino acids and cleared in urine and bile⁶. A 2026 review points out the paradox: a half-life of minutes against biological effects described over hours or days, and no pharmaceutical-grade formulation developed or validated, with no permeability or excipient-compatibility data¹³.

Because both peptides circulate mostly outside the pharmaceutical supply chain, batch quality is the variable that matters most. Anti-doping laboratories have identified them in confiscated vials and developed methods to detect them: BPC-157 in urine with a detection limit of 0.1 ng/mL and stable in urine for at least 4 days³, and TB-500 in horse urine and plasma by liquid chromatography-mass spectrometry³⁴. A label that says "TB-500" does not tell you whether it contains the 7-amino-acid fragment or the full protein¹⁶²⁴: only an identity test of the batch does.

To learn what a certificate of analysis measures and what it doesn't, see Peptide quality: a complete guide to COA, HPLC and purity and How to read a peptide certificate of analysis; for the chemistry of the lyophilized powder and the reconstituted vial, Peptide stability: from lyophilized powder to reconstituted vial.

Open questions and what to watch

• Do the animal results replicate in humans? The randomized, placebo-controlled hamstring phase 2 is the first serious test; its primary endpoints are time to unrestricted return to sport and MRI injury volume at day 14²⁹.
• Which molecule is active? For TB-500, the metabolite Ac-LKKTE may be the active one¹⁷; for BPC-157, a half-life of minutes does not fit effects lasting days¹³.
• Is there an oncologic risk? That depends on data that do not exist yet: long-term follow-up of exposed people²⁵²⁶.
• What is in the vial? Without a validated pharmaceutical formulation, every batch is an open question of identity, purity and impurities¹³²⁷.

The 2026 regulatory and commercial debate around these peptides is covered in BPC-157: from Rogan's podcast to an FDA vote and in LegitScript Opens Certification to BPC-157 and 5 Other Peptides. This guide will be updated when the registered trials report.